Literature DB >> 3347967

Radical prostatectomy. Patterns of local failure and survival in 67 patients.

P F Schellhammer1.   

Abstract

Sixty-seven patients with localized carcinoma of the prostate were treated by radical prostatectomy unaided by adjunctive hormonal therapy. Seven patients (10%) have been lost to follow-up, and 13 patients (19%) have died of other causes without evidence of prostate cancer. The crude or direct survival free of disease for traced patients with clinical Stage B1 nodules (11) and clinical B2 lesions (20) followed for at least fifteen years is 36 per cent and 25 per cent, respectively; the crude or direct survival free of disease for pathologic B (29) and C (12) tumors followed for fifteen years is 31 per cent and 8 per cent, respectively. The local failure incidence at fifteen years for pathologic Stage B tumors is 17 per cent and for pathologic C tumors 31 per cent. Capsular invasion alone on histologic examination did not increase the rate of local or distant failure above that noted for tumors that were entirely intracapsular. However, seminal vesicle invasion is associated with a 44 per cent local failure and 66 per cent distant failure rate. The interval between radical prostatectomy and first failure averaged sixty-nine months (median 56 months) and with hormonal therapy the interval between first failure and death averaged seventy months (median 62 months). The patients who underwent radical prostatectomy in this series represent 22 per cent of the 318 patients presenting with localized prostate cancer between 1960 and 1974. A 1.5-cm nodule was found in 5.5 per cent of the presenting population, and all but one of these patients were treated by radical prostatectomy.

Entities:  

Mesh:

Year:  1988        PMID: 3347967     DOI: 10.1016/0090-4295(88)90137-9

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  8 in total

Review 1.  [Optimizing the use of radiotherapy with IMRT and image guided location of advanced prostate cancer].

Authors:  F Lohr; M Fuss; U Tiefenbacher; M Siegsmund; S Mai; J M Kunnappallil; B Dobler; P Alken; F Wenz
Journal:  Urologe A       Date:  2004-01       Impact factor: 0.639

2.  Future directions for unsealed source radionuclide therapy for bone metastases.

Authors:  V R McCready; J M O'Sullivan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-08-16       Impact factor: 9.236

Review 3.  Evaluating radical prostatectomy specimens: therapeutic and prognostic importance.

Authors:  D G Bostwick; R Montironi
Journal:  Virchows Arch       Date:  1997-01       Impact factor: 4.064

4.  Radical pelvic surgery with preservation of sexual function.

Authors:  P C Walsh; P N Schlegel
Journal:  Ann Surg       Date:  1988-10       Impact factor: 12.969

5.  DNA-ploidy, G2M-fractions and prognosis of stages B and C prostate carcinoma.

Authors:  J G Müller; S Demel; M P Wirth; A Manseck; H G Frohmüller; H A Müller
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

6.  The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794.

Authors:  Gregory P Swanson; Bryan Goldman; Catherine M Tangen; Joseph Chin; Edward Messing; Edith Canby-Hagino; Jeffrey D Forman; Ian M Thompson; E David Crawford
Journal:  J Urol       Date:  2008-10-19       Impact factor: 7.450

7.  Detection of micrometastatic prostate cancer cells in the bone marrow of patients with prostate cancer.

Authors:  T Deguchi; M Yang; H Ehara; S Ito; Y Nishino; Y Takahashi; Y Ito; K Shimokawa; T Tanaka; T Imaeda; T Doi; Y Kawada
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 8.  The role of postoperative radiotherapy in prostate cancer patients.

Authors:  Małgorzata Zarzycka; Ewa Ziółkowska; Tomasz Wiśniewski; Wiesława Windorbska; Agnieszka Zyromska; Zbigniew Wolski
Journal:  Contemp Oncol (Pozn)       Date:  2013-10-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.